Jun. 3 at 12:01 PM
$CTMX - Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX’s PROBODY® and Regeneron's Veloci-Bi® platforms
- CytomX to receive
$37 million target selection payment for two additional programs selected
- Regeneron secures option to select up to 6 additional future targets bringing total potential target nomination, research, development, regulatory and sales-based milestones covered under the collaboration to up to approximately ~
$4 billion
